Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders |
NOVELION THERAPEUTICS INC. (NVLNF)
|
Add to portfolio |
|
|
Price: |
$0.71
| | Metrics |
OS: |
19.0
|
M
| |
|
|
Market cap: |
$13.5
|
M
| |
-67
|
% ROIC
|
Net debt:
|
$359
|
M
| |
|
|
EV:
|
$373
|
M
| | | |
| | | | | |
TTM Valuation | | | |
EBITDA
|
($15.7)
|
M
| |
|
|
EBIT
|
($42.4)
|
M
| |
|
|
EPS |
($5.69)
| |
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
In millions, except per share items | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 |
Revenues | 130.4 | 138.4 | 13.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Revenue growth | -5.8% | 919.9% | | | | | | |
Cost of goods sold | 59.7 | 77.2 | 6.0 | -26.0 | -32.2 | 0.0 | 0.0 | 0.0 |
Gross profit | 70.7 | 61.2 | 7.6 | 26.0 | 32.2 | 0.0 | 0.0 | 0.0 |
Gross margin | 54.2% | 44.2% | 56.0% | | | | | |
Selling, general and administrative | 79.8 | 96.5 | 29.5 | 16.2 | 17.7 | 7.0 | 15.1 | 17.1 |
Research and development | 38.8 | 49.0 | 14.8 | 9.8 | 13.8 | 18.5 | 24.6 | 23.0 |
EBITA | -22.8 | -59.2 | -25.9 | -23.3 | -5.1 | -26.5 | -40.8 | -41.4 |
EBITA margin | -17.5% | -42.8% | -190.6% | | | | | |
Amortization of intangibles | 25.1 | 25.1 | 2.1 | | | | | |
EBIT | -47.9 | -84.3 | -28.0 | -23.3 | -5.1 | -26.5 | -40.8 | -41.4 |
EBIT margin | -36.7% | -60.9% | -206.3% | | | | | |
Pre-tax income | -106.7 | -126.1 | -52.4 | -23.0 | -4.2 | -25.2 | -46.2 | -30.2 |
Income taxes | -1.6 | 0.6 | 0.5 | 0.0 | -0.2 | 0.6 | -3.9 | 1.2 |
Tax rate | 1.5% | | | | 4.6% | | 8.4% | |
Earnings from continuing ops | -108.3 | -126.7 | -52.9 | -23.0 | -3.9 | -25.8 | -42.3 | -31.4 |
Earnings from discontinued ops | | | | | -0.1 | | | 1.0 |
Net income | -108.3 | -126.7 | -52.9 | -23.0 | -4.0 | -25.8 | 45.7 | -30.4 |
Net margin | -83.0% | -91.5% | -389.5% | | | | | |
|
Diluted EPS | ($5.76) | ($6.81) | ($4.69) | ($2.21) | ($0.39) | ($0.51) | ($0.84) | ($0.63) |
Shares outstanding (diluted) | 18.8 | 18.6 | 11.3 | 10.4 | 10.2 | 50.9 | 50.1 | 50.1 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|